EGINITION Hospital
- Address
- 72-74 Vas.Sofias Ave., 11528 Athens, Greece
EGINITION Hospital - Neurodegenerative Disease Research
EGINITION Hospital operates as a specialized clinical research center with focused expertise in neurodegenerative disorders. The institution demonstrates significant commitment to advancing therapeutic options for patients with progressive neurological conditions through participation in multinational Phase 3 clinical trials evaluating novel treatment combinations.
- Amyotrophic Lateral Sclerosis (ALS) therapeutic interventions and combination therapy approaches
- Novel targeted therapies including tyrosine kinase inhibitors as add-on treatments to standard care
- Long-term safety and efficacy assessment in neurodegenerative disease management
The center's research portfolio emphasizes rigorous randomized, double-blind, placebo-controlled trials designed to evaluate both the efficacy and safety profiles of investigational agents combined with established therapies such as Riluzole. This systematic approach to evaluating combination treatment strategies positions EGINITION Hospital as an active contributor to the global effort in developing disease-modifying interventions for patients suffering from progressive motor neuron diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Ab Science2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ab Science2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EGINITION Hospital
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Masitinib Plus Riluzole Versus Placebo Plus Riluzole in Amyotrophic Lateral Sclerosis: A Phase 3 Randomized Controlled Trial | Ab Science | Phase III | Not Yet Recruiting | May 2021 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Masitinib | 2 | Unknown | 2021-05-24 | 2021-05-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.